Login / Signup

Proton Beam Therapy in the Oligometastatic/Oligorecurrent Setting: Is There a Role? A Literature Review.

Simona GaitoGiulia MarvasoCatalan R OrtizAdrian CrellinMarianne C AznarDaniel J IndelicatoShermaine PanGillian A WhitfieldFilippo AlongiBarbara Alicja Jereczek-FossaNeil BurnetMichelle P LiBethany Cordelia RothwellEd SmithRovel J Colaco
Published in: Cancers (2023)
PBT could represent an option for the treatment of oligometastatic/oligorecurrent disease in patients with a low metastatic burden. Nevertheless, due to its limited availability, PBT has traditionally been funded for selected tumour indications that are defined as curable. The availability of new systemic therapies has widened this definition. This, together with the exponential growth of PBT capacity worldwide, will potentially redefine its commissioning to include selected patients with oligometastatic/oligorecurrent disease. To date, PBT has been used with encouraging results for the treatment of liver metastases. However, PBT could be an option in those cases in which the reduced radiation exposure to normal tissues leads to a clinically significant reduction in treatment-related toxicities.
Keyphrases
  • squamous cell carcinoma
  • stem cells
  • small cell lung cancer
  • liver metastases
  • gene expression
  • risk factors
  • bone marrow
  • combination therapy
  • case report